Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New Hyde Park, New York


To determine what side effects and what clinical effects if any the administration of this investigational product, IDEC-152 (an antibody against CD23 which is an important protein on leukemia cells and certain cells in the body's immune system), has on the CLL patient population.


Inclusion Criteria: - Signed IRB-approved informed consent. - Greater than 18 years of age - Proof of CD23+ CLL or small lymphocytic lymphoma (SLL) - Progressive disease after at least 1 course of chemotherapy - Acceptable hematologic status, liver function, renal function, and pulmonary function - Patients of reproductive potential must agree to follow accepted birth control methods during treatment and for 3 months after completion of treatment Exclusion Criteria: - Previous exposure to IDEC-152 or other anti-CD23 antibodies - Presence of HIV infection or AIDS - Serious nonmalignant disease - Active uncontrolled bacterial, viral or fungal infections. - Clinically active autoimmune disease - Pregnant or currently breast feeding



Primary Contact:


Backup Contact:


Location Contact:

New Hyde Park, New York
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.